Streamline The AAV Manufacturing Process With High-Grade Starting Materials
Source: Forge Biologics
By Rachael Hardison, Ph.D., Manager, Technical Sales, Forge Biologics, and Don Belcher, Scientist II, Process Development, Forge Biologics
Plasmid DNA is one of the most common starting points for manufacturing recombinant adeno-associated virus (rAAV) vectors. As a gene therapy developer, carefully considering the manufacture and testing of plasmids is prudent for laying the groundwork for AAV manufacturing. Gene therapy developers need a depth of knowledge around the critical quality attributes of both plasmid DNA and the finished rAAV gene therapy product.
This article explores:
- Plasmid DNA Quality Characteristics to Consider in AAV Manufacturing
- Navigating the Path from Discovery to BLA with a Phased-Approach to Plasmid DNA
- Analytical Considerations When Generating Plasmid DNA for AAV Gene Therapies
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Forge Biologics
This website uses cookies to ensure you get the best experience on our website. Learn more